By Fineline Cube 
China-based Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096) announced that it has received marketing approval from the National Medical Products Administration (NMPA) for its suvemcitug, a next-generation anti-VEGF antibody co-developed with US firm Pyxis Oncology Inc. The Category 1 biologic drug is now approved for use in combination with paclitaxel, liposomal doxorubicin, or topotecan to treat adult patients with recurrent ovarian, fallopian tube, or primary peritoneal cancer that is platinum-resistant and has received no more than one prior line of systemic therapy.
First Targeted Therapy Approval
Suvemcitug is the first targeted therapy approved for all platinum-resistant ovarian cancer patient populations in China. It works by precisely blocking VEGF-receptor binding to inhibit tumor angiogenesis.
Clinical Advantages
The drug features a differentiated VEGF-binding epitope, demonstrating stronger inhibition of VEGF-VEGFR2 interaction compared to similar anti-VEGF antibodies. Preclinical models have shown superior anti-proliferative effects on vascular endothelial cells and tumor suppression.-Fineline Info & Tech